Fibroblast Activation Protein Inhibitor Imaging and Therapy in a Patient With Multiple Endocrine Neoplasia Type 2A Syndrome
Somaye Barashki, Ghasemali Divband, Emran Askari, Hamidreza Amini, Kamran Aryana
Abstract
ABSTRACT: A patient with multiple endocrine neoplasia type 2A syndrome who had exhausted several surgeries and radiotherapy was referred to nuclear medicine department for theranostic approaches. [68Ga]-DOTATATE PET/CT and [131I]I-mIBG SPECT/CT were performed, but the degree of uptake was insufficient for using the treatment companion of these tracers. Finally, 1 year later, [68Ga]-FAPI-46 PET/CT showed progressive disease with metastases to the lung, liver, bone, and lymph nodes with intense [68Ga]-FAPI-46 uptake. Treatment with [177Lu]Lu-FAPI-46 was done, and the patient tolerated treatment and showed evidence of clinical improvement following therapy.
Topics & Concepts
MedicineFibroblast activation protein, alphaLymphMultiple endocrine neoplasiaEndocrine systemRadiation therapyPathologyDiseaseInternal medicineCancer researchOncologyRare diseaseProgrammed cell death 1FibroblastProgressive diseaseEndocrine diseasePositron Emission Tomography-Computed TomographyMultiple endocrine neoplasia type 2GastroenterologyPeptidase Inhibition and AnalysisNeuroendocrine Tumor Research AdvancesConnective tissue disorders research